TallowTallow
Tallow Research

Why Tallow won't sell peptides or GLP-1s

Olive now sells compounded GLP-1s. Oasis tests and ranks gray-market peptides. Two 'clean' apps went off the rails for the money. Why Tallow never will.

Maddox Schmidlkofer

Close-up of a syringe needle with a drop of liquid at its tip.

On October 10, Oasis, the app a lot of you use to check your bottled water, published a lab report on a vial of retatrutide it bought from a "research peptide" website. Retatrutide is Eli Lilly's next weight-loss drug. It isn't approved anywhere in the world. The vial was labeled 10 mg, held 11.81 mg, and had arsenic in it. Oasis gave it 100 out of 100.

Four days later, Oasis published a ranking of the "Top 20 Peptide Providers in 2026."

Meanwhile Olive, the seed-oil scanner, renamed itself on the App Store. It's now "Olive: AI Health & Weight Loss," and its website sells compounded semaglutide and tirzepatide starting at $199 a month, with Klarna if you want to pay it off later.

Think about that. Two apps that built their whole brand on "clean," on real food and on getting toxins out of your life, are now pushing injectables. One sells them. The other tests them, gives them perfect scores, and ranks who to buy them from. That's an endorsement, whatever the footnote says.

They've gone completely off the rails from what they stood for, and I think it's because peptides are where the money is right now. People keep asking us when Tallow is adding peptides, so I want to be clear about where we stand.

We're not. Tallow will never sell you a GLP-1, a peptide, or anything you inject, and we won't score them either.

(Disclosure: I build Tallow, which competes with Olive and Oasis. Everything below about them is from their own websites and App Store listing as of October 22, 2026, and I link to all of it so you can check.)

Why everyone is suddenly searching "peptides"

You've probably noticed peptides everywhere. It isn't just your feed. I pulled Google Trends for the US before writing this:

  • Searches for "peptides" tripled between October 2025 and their peak in April 2026, and they're still about 50% above where they were a year ago.
  • On October 19, searches for "GLP-1" jumped about tenfold in a few hours. The rising query was "compounded GLP-1 nationwide recall."
  • Breakout searches this week include "HHS interim access policy peptides," "FDA ruling on peptides," and "is reta safe." ("Reta" is what people online call retatrutide.)

Here's what's behind each of those.

What actually happened this month

The recall. A North Carolina compounding pharmacy, Apothecary Pharma, recalled compounded tirzepatide vials (plus one vial of NAD+) that had been shipped nationwide, because "their sterility cannot be assured." FDA classified it as a Class II recall on October 8. To be fair, it was small: 22 tirzepatide vials. FDA had already sent the same pharmacy a warning letter in December 2025. But it's a good reminder of what "compounded" means. It's made by a pharmacy, not the drugmaker, and it isn't FDA-approved.

The peptide policy. On October 15, the AP reported that HHS had sent an "interim access policy" for peptides to the White House budget office. According to two anonymous sources, it would temporarily let pharmacies compound peptides like BPC-157. The text isn't public yet. Even if it goes through, it would be FDA choosing not to enforce, not FDA approving anything. FDA's own staff have said none of these peptides have been studied enough to show they're safe and effective.

The vote that set it up. In July, an FDA advisory committee voted to put BPC-157, TB-500 and four other peptides back on the list pharmacies can compound from. FDA staff opposed it. Time reported that the yes votes came mostly from members who represent or advise telehealth companies, and that telehealth companies lobbied for it.

So the people who sell peptides helped vote peptides back in. Keep that in mind.

The Wild West part

There are two different markets here, and both are messier than the marketing:

1. Compounded GLP-1s from telehealth. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were in shortage for years, so FDA let pharmacies make copies. Both shortages officially ended by February 2025. The compounding didn't. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, some needing hospitalization, some from dosing mistakes.

2. "Research use only" peptides. These are the vials sold online with a "not for human consumption" label that everyone ignores: retatrutide, BPC-157, TB-500, CJC-1295. In 2026 alone:

  • FDA sent warning letters to at least nine of these sellers in March, June and August, most of them for selling retatrutide.
  • In August, Eli Lilly sued six of them, including Astra Peptides, Texas Peptides and Lone Star Peptide, over fake retatrutide. Lilly says it's reported more than 200 sellers to authorities.
  • In July, a federal judge in South Bend, Indiana, sentenced the owner of Paradigm Peptides to 70 months in prison. Paradigm sold to about 54,000 customers, faked its lab certificates, and every testosterone-like product the government tested had real testosterone in it. (CBS News)

That last one hits close to home. I'm in Indiana. The case was mostly about testosterone-like compounds, not GLP-1s, but they were sold by a company with "Peptides" in its name, to people who thought they were buying something clean. That's the market we're talking about.

What Olive is selling

Olive's App Store subtitle is now "Habits, Food, Peptides & GLP-1." Its weight-loss page is titled "The GLP-1 Program Designed to Get You Off GLP-1s," and it offers:

WhatOlive's description
GLP-1sCompounded semaglutide or tirzepatide, "dosed to you"
Price"From $199/mo," with Klarna buy-now-pay-later
Other protocolsGLP-1 "microdosing," NAD+, sermorelin, glutathione, B12
Who prescribesClinicians through OpenLoop Health, a telehealth company

Olive's medical board lists one doctor for "peptide therapy oversight" and Dr. Chris Knobbe, the seed-oil researcher. And in its own FAQ, Olive says compounded drugs "are not approved or evaluated for safety, effectiveness, or quality by the FDA."

I'll give Olive this: it goes through licensed clinicians and pharmacies, not research-chemical websites. But remember what Olive was. It was the seed-oil app. The holistic one. Its pitch was that your food is the problem and real food is the fix, and it put an ancestral-diet doctor on its board to prove it.

Now the fix is a $199-a-month injection of a drug the FDA hasn't approved in that form. You scan your groceries, the app tells you your food is making you sick, and then it sells you the shot. The scanner has become the funnel.

Follow the money. Olive's App Store subscription tops out around $70 a year. The GLP-1 program starts at $199 a month. That's more than 30 times as much, and it isn't hard to guess which one the company is built around now.

What Oasis is doing

Oasis doesn't sell peptides. It does something I think is just as bad: it tests them, scores them, and tells you which sellers are best.

Peptides are now an official scoring category on Oasis, tested for identity, potency, heavy metals and endotoxin (that last test only matters for something you inject). In October it published two posts:

Both posts have disclaimers. Oasis says the score "is not a medical endorsement" and the ranking is "not a recommendation to inject research peptides."

I don't buy it. Testing a product, giving it a perfect score and ranking the 20 best places to get it is endorsing it. You don't make a buyer's guide for something you think people shouldn't buy. Most people see a green 100/100 and never read the footnote, and Oasis knows that better than anyone, because that's how its scores work on everything else.

This is an app that built its name on finding arsenic in your bottled water. Here it gave a perfect score to something you inject that had arsenic in it. And "100/100" on a vial with almost 20% more drug than the label says is a strange kind of perfect. If you're dosing off that label, you're taking more than you think.

I couldn't find any affiliate deal between Oasis and these sellers. I don't think it needs one. Peptides are the most-searched thing in wellness right now, and "Top 20 Peptide Providers" is how you get that traffic.

They forgot what they were for

People downloaded Olive and Oasis to get less stuff in their bodies. Fewer seed oils, less plastic, no heavy metals. That was the whole promise.

Unapproved injectables are the opposite of that promise. There's no long-term human data on most of these peptides. The "research" vials come from a market FDA, Lilly and federal prosecutors are all trying to shut down. If an app told you a snack was fine because one bag passed one test, you'd laugh. That's exactly what a 100/100 on a peptide vial is.

I get why they did it. Peptides are the biggest trend in wellness, and there's real money in them. But once your health app makes money when you inject something, you're not a clean-living app anymore. You're a supplement shop with a scanner attached.

Where Tallow stands

Here's our line, plainly:

  1. We will never sell GLP-1s, peptides, or any injectable. Not through a telehealth partner, not as an affiliate link, not as a "protocol."
  2. We won't score injectable peptides. A score from us means "this is clean enough to eat." I'm not putting that kind of signal on a research chemical.
  3. We're not judging anyone on a GLP-1. If you and your own doctor decided on an FDA-approved drug, that's your call and it's none of our business. What we're against is the gray market, and food apps steering their users into it.
  4. We'll keep doing the boring thing. Tell you what's in your food, who tested it, and where a restaurant's seed oils are hiding. That's the whole job.

The reason is simple. The moment an app makes money when you buy a drug, it has a reason to tell you your food is the problem and the drug is the fix. I don't want Tallow to have that reason.

Fair question: doesn't Tallow make money from brands? Yes. Brands can pay for placement, and we say so. No payment has ever moved a score. That's a lot different from selling you the cure for the problem your scan just found.

If you're looking to buy peptides

Don't. Go to the gym.

Seriously. Do not inject something into your body that you bought off a website, that a 20-something on TikTok swears by, or that an app scored 100/100. "For research use only" means nobody checked it was safe for you. "Compounded" means the FDA never approved it. Even Olive says so.

Everything people are buying peptides for, the gym and real food already do. Lift heavy things. Walk every day. Eat protein, real fat and food your great-grandparents would recognize. Cut the seed oils and the ultra-processed stuff. Sleep. It's slower than a needle, it's free, and nobody's selling it to you at $199 a month.

If you have an actual medical condition, talk to your own doctor, not one an app picked because the app gets paid when they say yes. (I'm not a doctor, and this isn't medical advice.)

And if you want help with the real food part, that's what Tallow is for. Scan your pantry and see what's actually in it.

Eat clean. Drink clean.

Sources: Olive's App Store listing, weight-loss page and refund policy (OpenLoop Health); Oasis's peptide scoring method, Oct 10 testing post and Oct 14 provider ranking, all as of October 22, 2026. Apothecary Pharma recall via Fox Business (Oct 20, 2026). HHS interim access policy via the AP (Oct 15, 2026). FDA adverse event counts and warning letters. Advisory committee vote via Time. Paradigm Peptides sentencing via CBS News. Search data from Google Trends (US), checked October 22, 2026.